Dan LeBatard offers the most intelligent and mature take on PEDs in sports I’ve seen in ages. He asks us to take a step back and ask ourselves why it is we are so hung up on a certain, narrow kind of performance enhancement in sports when we never question it — indeed, we openly praise it — when athletes do insane things to their bodies, all in the name of staying on the field? Often things that could cause massive harm.
Stuff like Ronnie Lott cutting his finger off. Lomas Brown playing with a catheter. Players having ligaments taken from cadavers and inserted into their own bodies. Drug therapies and medical procedures that are wholly unnecessary for a normal quality of life but are accepted in the name of athletic performance. We are totally fine with these. We are not totally fine with others:
We are OK with Kirk Gibson hitting one of the most famous home runs ever on one steroid (cortisone), but we slam the Hall of Fame door on the face of everybody else who might have used the anabolic kind. Granted, cortisone is not a banned performance enhancer, but it certainly enhanced Gibson’s performance, which wouldn’t have been possible without it. Lost in the shouting of “Cheater!” and “Fraud!” from a pill-popping America is how often athletes have to go through the pharmacy for the healing properties of hormones — not just to hit home runs but because what they do for a daily living really hurts.
It is not enough to draw some line and say “well, [drug/procedure X] is banned and [drug/procedure Y] is not banned.” It makes people who like to pour crap on banned PED users feel better, but it’s a most pedantic distinction. Why are some procedures and drugs banned and others not? Why do we allow some sorts of performance enhancement or enabling but not others? If it’s OK for Kirk Gibson to take a drug that allowed him to take the field when he otherwise could not have, why do we not allow other players to take other drugs that allow them to take the field when they otherwise can’t?
More broadly, as fans and observers, why do we seem to care so much and get so annoyed at certain sorts of seemingly unnatural acts undertaken by athletes but don’t care a bit — or, alternatively, fully expect — so many others?
Jon Heyman of CBS Sports reports that the Blue Jays have narrowed their search for a new general manager down to two candidates: current interim GM Tony LaCava, and Indians vice president of player personnel Ross Atkins. Former Jays GM Alex Anthopoulos resigned last month.
LaCava was promoted to interim GM on November 2 and has already made a handful of moves along with new president Mark Shapiro. The club acquired Jesse Chavez in a trade and signed pitchers Marco Estrada and J.A. Happ to multi-year deals.
Atkins worked under Shapiro in the Indians organization for 15 seasons, so it is no surprise that he is a finalist for the open GM position.
Update (7:58 PM EST): Nick Piecoro of the Arizona Republic reports that Diamondbacks GM Dave Stewart met with Cueto earlier this month in the Dominican Republic and made a contract offer that the right-hander turned down. The Diamondbacks maintain interest in the free agent.
Ken Rosenthal of FOX Sports reports that the Diamondbacks spoke with Bryce Dixon, the agent of free agent starter Johnny Cueto. However, Rosenthal notes that Cueto’s price tag is expected to exceed the Diamondbacks’ comfort level.
Cueto, 29, is one of a handful of highly touted starting pitchers in this offseason’s free agent class. He is joined by David Price and Zack Greinke, among others. Jordan Zimmermann inked a deal in the neighborhood of $110 million over five years with the Tigers on Sunday morning, which will serve as a barometer for Cueto.
Cueto finished the 2015 regular season, between the Reds and the Royals, with a 3.44 ERA and a 176/46 K/BB ratio over 212 innings. He made 13 shaky starts with the Royals, but outside of a shellacking in Game 3 of the ALCS against the Blue Jays, pitched well in the post-season. Cueto pitched a complete game in Game 2 of the World Series against the Mets, helping put the Royals up two games to none at the time.
As a result of switching teams during the season, Cueto was not eligible to receive a $15.8 million qualifying offer. This means that Cueto, unlike Zimmermann for example, does not come attached with draft pick compensation.
Nick Cafardo provides this interesting nugget in his Sunday notes column at the Boston Globe …
Hanley Ramirez, 1B-DH, Red Sox — There’s now talk in the front office that Dave Dombrowski is trying to move Ramirez in a deal. The Mariners, Orioles, and Angels seem to be the targets, and all three make sense.
Cafardo notes that “there are huge hurdles to cross” before a trade could happen — like how much of Hanley’s remaining salary the Red Sox would have to eat and what positions the soon-to-be 32-year-old is able to play defensively at this point in his career.
Boston’s higher-ups have asked Ramirez to learn first base and drop 20 pounds this winter. Whatever team is looking to acquire him would probably have to be comfortable with him serving primarily as a designated hitter.
Hanley is owed $68.2 million over the next three seasons and he carries a $22 million vesting option for 2019. He batted just .249/.291/.426 in 105 games this past year.
Ben Zobrist posted a cool .809 OPS (120 OPS+) in 126 games this summer between Oakland and Kansas City while appearing defensively at second base, third base, and both corner outfield positions.
His steady bat and defensive versatility make him a fit for just about every club in Major League Baseball, and the defending National League champions are among the teams in hot pursuit …
It’s a little odd to see the rebuilding Braves listed there given that Zobrist is 34 years old, but Rosenthal says the interest stems from a “desire for him to serve as [a] model for younger players” as the club prepares to open a new ballpark in 2017. Wasn’t that supposed to be Nick Markakis‘ job?
Zobrist and his agent Alan Nero are believed to be seeking a four-year deal.